Clinical Trials Sponsored by GRADE Onlus

Total 904 results

Fondazione Italiana Linfomi ONLUS
GRADE Onlus

Recruiting

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy (FIL_PREVID)

Diffuse Large B-Cell Lymphoma | Elderly Patients

Italy
CNS Onlus

Not yet recruiting

Transcranial Photobiomodulation for Adult ADHD

ADHD
Uniter Onlus

Completed

Metabolic and Chronobiological Changes in Vestibular Rehabilitation

Sleep Disorder | Metabolic Disease | Vestibular Disorder

Italy
Arcispedale Santa Maria Nuova-IRCCS
University of Modena and Reggio Emilia; GRADE Onlus

Completed

Therapeutic Education in Physical Activity (ETAF) (ETAF)

Hematologic Neoplasms

Italy
Tages Onlus

Recruiting

Evolutionary Systems Therapy for Schizotypy (ESTS-RCT)

Schizotypal Personality Disorder

Italy
Tages Onlus

Completed

Mindful Compassion for Perfectionism (MCP)

Perfectionism

Italy
Tages Onlus

Completed

Compassion and Metacognition in Schizotypal Personality (CMBT)

Schizotypal Personality Disorder

Italy
CNS Onlus

Unknown

Modulating Inhibitory Control Networks in Gambling Disorder With Theta Burst Stimulation (TMS-GD)

Gambling Disorder

Italy
Fondazione GISE Onlus

Not yet recruiting

in Patients With SCAD Undergoing Complex PCI, the RESPONSE Study"

Coronary Disease

Italy
Fondazione Melanoma Onlus

Withdrawn

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Melanoma

Italy
Fondazione Melanoma Onlus

Completed

Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation (VEMUPLINT)

Melanoma

Italy
Fondazione Melanoma Onlus

Active, not recruiting

Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

Italy
Emergency NGO Onlus

Withdrawn

Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) (EASE)

Ebola Virus Disease
Fondazione EMN Italy Onlus

Active, not recruiting

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Active, not recruiting

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients (MPRvsMEL200)

Multiple Myeloma | Newly Diagnosed Patients

Italy
Fondazione EMN Italy Onlus

Active, not recruiting

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Completed

Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

Multiple Myeloma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

Hepatitis C | Indolent B-cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Active, not recruiting

Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL (FIL_KLIMT)

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL (FIL-RBAC500)

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Active, not recruiting

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Relapsed T-Cell Lymphoma | Refractory T-Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Follicular Non-Hodgkin's Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Terminated

Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients (GIOTTO)

Diffuse, Large B-Cell, Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Terminated

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting (FIL-BBV)

Lymphatic Diseases

Italy
Fondazione EMN Italy Onlus

Terminated

Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment (PO-3887)

Multiple Myeloma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. (FIL_BVHD01)

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM

Lymphoma, Large B-Cell, Diffuse

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients (MCL0208)

MANTLE CELL LYMPHOMA

Italy, Portugal
Fondazione Italiana Linfomi ONLUS

Completed

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

B-Cell Lymphomas

Italy, Brazil
Fondazione Italiana Linfomi ONLUS

Unknown

Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters

Lymphoblastic Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL (ANZINTER3)

Diffuse Large B Cell Lymphoma (DLBCL) | Elderly Patients (>65 Years)

Italy
Fondazione EMN Italy Onlus

Recruiting

Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

Multiple Myeloma

Italy
Fondazione Italiana Linfomi ONLUS

Recruiting

Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Classical Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Recruiting

Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

Non Hodgkin Lymphoma

Italy
Fondazione EMN Italy Onlus

Completed

Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients (RP_MPR)

Multiple Myeloma
Fondazione EMN Italy Onlus

Completed

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Active, not recruiting

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients (DPd)

Multiple Myeloma | Deletion 17P Syndrome

Italy
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Diffuse Large B-cells Non-Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

"MIRO" Molecularly Oriented Immuno-radio-therapy (FIL_MIRO)

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Lymphatic Diseases

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's (FIL_BRB)

Waldenstrom's Macroglobulinemia

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

Follicular Lymphoma

Italy
Fondazione EMN Italy Onlus

Completed

Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD) (MRD)

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Completed

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

Multiple Myeloma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL (R2-B)

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Relapsed/Refractory Hodgkin's Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL

Diffuse Large B-cell Lymphoma

Italy

3

Subscribe